XETRA · Healthcare
Invest in Newron Pharmaceuticals stock from India
Indian and foreign residents can buy Newron Pharmaceuticals (NP5) shares directly through Paasa.
By Paasa · Updated
Newron Pharmaceuticals at a glance
- Price
- €8.50-€0.30 (3.41%)
- Market cap
- €176.85M
- Day range
- €8.50 – €8.92
- P/E
- -5.83
- Dividend yield
- None
- Volume
- 6.02K
- 1 month
- -35.61%
- 6 months
- -48.67%
- YTD
- -67.74%
- 1 year
- -25.57%
- 5 years
- +329.29%
Newron Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €19.1M | €51.4M | €9.1M | €6.1M | €5.8M |
| Gross profit | €19.1M | €51.4M | €9.1M | €6.1M | €5.8M |
| Operating income | −€4.7M | €26.2M | −€11.6M | −€13.3M | −€12.4M |
| Net income | −€13.3M | €15.8M | −€16.2M | −€17.5M | −€14.9M |
| Earnings per share | −€0.67 | €0.85 | −€0.91 | −€0.98 | −€0.84 |
| EBITDA | −€4.6M | €25.9M | −€11.8M | −€13.3M | −€12.2M |
| Total assets | €40.0M | €63.9M | €25.9M | €37.2M | €50.5M |
| Total debt | €38.1M | €50.5M | €48.4M | €45.7M | €43.1M |
| Cash and short-term investments | €28.9M | €9.8M | €12.6M | €22.8M | €34.6M |
| Shareholders' equity | −€11.1M | €1.5M | −€29.9M | −€14.0M | €3.1M |
| Operating cash flow | €32.6M | −€17.6M | −€10.1M | −€11.1M | −€11.4M |
| Free cash flow | €32.5M | −€17.6M | −€10.2M | −€11.1M | −€11.5M |
| Capital expenditure | −€47.3K | −€13.0K | −€11.0K | −€18.0K | −€20.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| M1 Kliniken | M12.DE | €20.70 | €388.71M |
| Formycon | FYB.DE | €19.34 | €341.79M |
| Zura Bio | 94E.F | €3.48 | €330.59M |
| Medios | ILM1.DE | €11.16 | €284.64M |
| Stratec | SBS.DE | €22.00 | €267.43M |
| Mediclin | MED.DE | €5.30 | €251.75M |
| High Tide | 2LYA.F | €2.38 | €209.13M |
| Heidelberg Pharma | HPHA.DE | €2.36 | €110.41M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Newron Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search NP5 and buy
Find Newron Pharmaceuticals by name or by its ticker, NP5, and place your order.
Why invest in Newron Pharmaceuticals from India
What Newron Pharmaceuticals does
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Newron Pharmaceuticals operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Newron Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy Newron Pharmaceuticals (NP5) shares directly through Paasa. Newron Pharmaceuticals is listed on XETRA, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are Newron Pharmaceuticals dividends taxed for Indian investors?
Newron Pharmaceuticals trades on XETRA but is domiciled in Italy, so any withholding on its dividends follows that country's rules rather than those of Germany. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Newron Pharmaceuticals shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.